HomeCONGRESS

CONGRESS

View Category
Day 2

From Horizons to Euromax: Bivalirudine or UFH/IIbIIIa?

Stone, Gregg W. (USA )2014-04-24
solaci -
Learn More
Day 2

DES with reabsorbable polymers are the best choice

Granada, Juan (USA)2014-04-24
solaci -
Learn More
Day 3

MSC -HF Trial: Auto mesenchymal cell transplantation may improve ventricular function in patients with heart failure of ischemic cause

This study is a phase 2, randomized 2:1, double blind, and placebo-controlled included 59 patients with advanced...
solaci -
Learn More
Day 3

ZEUS Trial: Patients with increased risk of bleeding may benefit from eluting stents Zotarolimus

The use of drug-eluting stents versus bare metal stents is controversial in some clinical situations in patients...
solaci -
Learn More
Day 3

NEXT Trial: Biodegradable polymer stent (Nobori) was similar to the permanent polymer stents (Xience / Promus) at 2 years.

This multicenter work from Japanrandomized 3200 patients to receive biodegradable polymer biolimus eluting stent(Nobori) or everolimus-eluting stent...
solaci -
Learn More
Day 3

SIRS Trial: Methylprednisolone does not decrease mortality and increase the risk of stroke in patients undergoing cardiac surgery

Cardiac surgery with cardiopulmonary bypass results in an inflammatory response of the body that is usually associated...
solaci -
Learn More
Day 3

STAMPEDE Trial: Bariatric surgery was superior to optimal medical therapy to glycemic control in obese type 2diabetics

In the short term, bariatric surgery showed improvement in glycemic control of obese type 2 diabetics.This study...
solaci -
Learn More
Day 3

POISE -2: Aspirin before a noncardiac surgery does not reduce the risk of death or myocardial infarction and increased bleeding.

There is great variability in the perioperative administration of aspirin (ASA) in patients undergoing noncardiac surgery, both...
solaci -
Learn More